Belite Bio reported positive Phase 3 DRAGON secondary endpoint data for tinlarebant in Stargardt disease and completed its FDA NDA submission.
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
Belite Bio has presented additional positive Phase 3 data for tinlarebant (LBS-008) in Stargardt disease type 1 (STGD1), strengthening evidence for what could become the first approved treatment for the inherited retinal disease. The findings, presented during the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montréal, expand on previously reported topline results from the pivotal DRAGON trial and provide new supportive evidence from key secondary endpoints.
The company has also completed its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA), moving tinlarebant into regulatory review and one step closer to potentially becoming the first approved therapy for patients with STGD1.
Tinlarebant Targets Vitamin A-Derived Retinal Toxins
Tinlarebant is an investigational oral retinol-binding protein 4 (RBP4) inhibitor that reduces the delivery of vitamin A (retinol) from the liver to the eye. By lowering retinal retinol levels, the therapy reduces the formation of toxic vitamin A-derived by-products known as bisretinoids, which accumulate in patients with STGD1 and contribute to progressive retinal degeneration.
STGD1 is the most common inherited macular dystrophy in children and young adults. The disease is caused by mutations in the ABCA4 gene, leading to progressive central vision loss. Despite its substantial impact on vision and quality of life, no approved therapies are currently available.
Tinlarebant has received multiple regulatory incentives, including Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the United States, as well as Orphan Drug designation in Europe, Japan, and Switzerland and Sakigake designation in Japan.
Phase 3 DRAGON Trial Demonstrated Clinically Meaningful Benefit
The global Phase 3 DRAGON trial (NCT05244304) enrolled 104 patients with STGD1 across 11 jurisdictions and randomly assigned participants in a 2:1 ratio to receive tinlarebant or placebo.
Previously reported topline results showed the study met its primary efficacy endpoint, demonstrating a statistically significant and clinically meaningful 35.7% reduction in the growth rate of retinal lesions, measured by definitely decreased autofluorescence (DDAF), compared with placebo.
The newly presented secondary endpoint analysis focused on quantitative autofluorescence (qAF), an imaging biomarker that reflects retinal bisretinoid accumulation. After 25 months of treatment, patients receiving tinlarebant maintained stable to slightly reduced qAF values, with an approximate 2% decrease from baseline. In contrast, placebo-treated patients experienced an approximately 20% increase from baseline, indicating continued accumulation of toxic retinal by-products.
These findings are consistent with tinlarebant’s proposed mechanism of action and provide additional biological evidence supporting its ability to modify disease progression. However, qAF is a biomarker endpoint rather than a direct measure of visual function, and the therapy’s long-term effect on functional vision outcomes continues to be evaluated.
Tinlarebant was well tolerated throughout the Phase 3 study, with no new safety concerns reported during the ASRS presentation. Although the current safety profile remains encouraging, continued long-term safety monitoring will be important because patients with STGD1 may require prolonged treatment.
Secondary Endpoint Data Reinforce Treatment Effect
Belite Bio Chairman and Chief Executive Officer Dr. Tom Lin said the additional analyses strengthen confidence that tinlarebant can meaningfully slow retinal lesion progression in STGD1. He noted that presenting the data at ASRS, one of the leading international meetings for retinal specialists, supports the ongoing regulatory review as the company works toward making the first treatment for Stargardt disease available to patients.
Chief Medical Officer Dr. Hendrik Scholl said the stable qAF findings reinforce the consistency of the treatment effect and align with tinlarebant’s mechanism of reducing bisretinoid accumulation, a key driver of retinal damage in STGD1.
FDA Review Marks the Next Milestone
With the NDA now under FDA review, tinlarebant has entered the next stage of its regulatory journey. If approved, it would become the first authorized treatment for Stargardt disease type 1, addressing a longstanding unmet medical need for patients with this progressive inherited retinal disorder. The combination of positive primary endpoint results, supportive biomarker data, and a favorable safety profile provides the evidence underpinning the ongoing regulatory assessment as Belite Bio advances toward potential commercialization.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.